儿童髓鞘少突胶质细胞糖蛋白抗体相关疾病临床分型及治疗进展

Clinical classification and treatment progress of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

髓鞘少突胶质细胞糖蛋白(MOG)特异性表达于CNS少突胶质细胞质膜和髓鞘最外层,易于与抗体结合成为自身抗体介导疾病的潜在靶标,目前已在多种获得性CNS脱髓鞘疾病(ADS)中发现MOG抗体。MOG抗体引起的ADS致病机制尚不明确,临床表型多样,儿童更为明显,当前缺乏统一的治疗指南。本文就以上多个方面等展开综述,提高对疾病的认识,并对今后更好的诊断和治疗提供借鉴意义。

Myelin oligodendrocyte glycoprotein(MOG)is expressed exclusively on the outer surface of the myelin sheath and and plasma membrane of oligodendrocytes in CNS and is easily combined with antibodies to become a potential target for autoantibody-mediated diseases.MOG antibodies are found in a variety of acquired demyelinating syndromes(ADS)of the CNS.The pathogenic mechanism of ADS caused by MOG antibodies is still unclear.The clinical phenotypes are diverse,and it is more obvious in children.At present,there is no unified treatment guideline.This article summarizes the above aspects,improves the understanding of the disease,and provides reference for better diagnosis and treatment in the future.